GlaxoSmithKline Hides Knowledge that It’s Drug Increases Heart Risks

The Food and Drug Administration (FDA) resolved to hold a two-day hearing to inspect the reports filed regarding the side effects of GlaxoSmithKline's drug Avandia. The defective drug is thought to increase the chance of heart attacks. These allegations, if proven correct, would result in the drug being withdrawn from the market.

SmithKline Beecham, the owner of GlaxoSmithKline, had taken up some researches to find out whether his drug was much healthier on hearts than its competitor, Actos.

Although these researches concluded that GlaxoSmithKline's drug was not safer, and even more dangerous than Actos, SmithKline Beecham did not report the results to the federal drug regulators and instead tried to hide it for the next eleven years.

Information about the heart risks was well-known for the Executives of GlaxoSmithKline shortly after the drug was released in 1999.

Senator Max Baucus of Montana, also Chairman of the Senate Finance Committee, stated “When drug companies withhold data regarding safety concerns about their medicines, they put patients at risk”.

GlaxoSmithKline had a history in hiding negative clinical trials, as in 2004, researches of GlaxoSmithKline held back some results about their antidepressant, which was proved to increase suicidal thoughts in teenagers and children.